{"DataElement":{"publicId":"2984453","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy Malignant Testicular Germ Cell Tumor Status Type","preferredDefinition":"A description of the best response to therapy for malignant testicular germ cell tumor.","longName":"2946463v1.0:2984433v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2946463","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"747EBAC6-25E8-A734-E040-BB89AD43588E","latestVersionIndicator":"Yes","beginDate":"2009-09-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2984433","version":"1","preferredName":"Malignant Testicular Germ Cell Tumor Status Type","preferredDefinition":"A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor. -- 2004_A condition or state at a particular time._Type; a subdivision of a particular kind of thing.","longName":"2984433v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Toxic death","valueDescription":"Therapy-Related Toxicity Death","ValueMeaning":{"publicId":"3345073","version":"1","preferredName":"Therapy-Related Toxicity Death","longName":"3345073","preferredDefinition":"The finding of bodily harm due to the poisonous effects associated with the action or administration of therapeutic agents.: The absence of life or state of being dead.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy-Related Toxicity","conceptCode":"C42607","definition":"The finding of bodily harm due to the poisonous effects associated with the action or administration of therapeutic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"CASP1 Gene","conceptCode":"C26554","definition":"This gene plays a role in apoptosis, inflammation, septic shock, and wound healing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B5E2C84B-6EB0-CE4C-E040-BB89AD435B04","latestVersionIndicator":"Yes","beginDate":"2012-01-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B642B920-1BEA-ABA3-E040-BB89AD437679","beginDate":"2010-01-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-01-11","modifiedBy":"ONEDATA","dateModified":"2012-01-11","deletedIndicator":"No"},{"value":"Complete response","valueDescription":"Complete response","ValueMeaning":{"publicId":"3260648","version":"1","preferredName":"Complete response","longName":"3260648","preferredDefinition":"Absence of clinically detectable disease including normal HCG and AFP and normalization of previously abnormal radiographic studies for at least one month","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9C54027-E9CB-5C4A-E040-BB89AD436EC6","latestVersionIndicator":"Yes","beginDate":"2011-08-05","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C54027-E9E3-5C4A-E040-BB89AD436EC6","beginDate":"2010-01-12","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"ONEDATA","dateModified":"2011-08-05","deletedIndicator":"No"},{"value":"Continued complete response","valueDescription":"Continued complete response","ValueMeaning":{"publicId":"3260649","version":"1","preferredName":"Continued complete response","longName":"3260649","preferredDefinition":"Continued absence of all disease after a complete response to a previous line of therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9C54027-E9ED-5C4A-E040-BB89AD436EC6","latestVersionIndicator":"Yes","beginDate":"2011-08-05","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C54027-EA05-5C4A-E040-BB89AD436EC6","beginDate":"2010-01-12","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"ONEDATA","dateModified":"2011-08-05","deletedIndicator":"No"},{"value":"Markers elevated","valueDescription":"Markers elevated","ValueMeaning":{"publicId":"3260650","version":"1","preferredName":"Markers elevated","longName":"3260650","preferredDefinition":"No measurable disease, but tumor markers elevated","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9C54027-EA0F-5C4A-E040-BB89AD436EC6","latestVersionIndicator":"Yes","beginDate":"2011-08-05","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C54027-EA28-5C4A-E040-BB89AD436EC6","beginDate":"2010-01-12","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"ONEDATA","dateModified":"2011-08-05","deletedIndicator":"No"},{"value":"No response","valueDescription":"No response","ValueMeaning":{"publicId":"3260651","version":"1","preferredName":"No response","longName":"3260651","preferredDefinition":"Less than 50 percent reduction in disease or tumor markers.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9C54027-EA32-5C4A-E040-BB89AD436EC6","latestVersionIndicator":"Yes","beginDate":"2011-08-05","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C54027-EA4A-5C4A-E040-BB89AD436EC6","beginDate":"2010-01-12","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"ONEDATA","dateModified":"2011-08-05","deletedIndicator":"No"},{"value":"Partial response","valueDescription":"Partial response","ValueMeaning":{"publicId":"3260653","version":"1","preferredName":"Partial response","longName":"3260653","preferredDefinition":"Greater than or equal to 50 percent reduction in the sum of the perpendicular diameters of measureable lesions for greater than or equal to 1 month and/or greater than or equal to 50 percent reduction in tumor markers","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9C54027-EA77-5C4A-E040-BB89AD436EC6","latestVersionIndicator":"Yes","beginDate":"2011-08-05","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C54027-EA8F-5C4A-E040-BB89AD436EC6","beginDate":"2010-01-12","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"ONEDATA","dateModified":"2011-08-05","deletedIndicator":"No"},{"value":"Progressive disease","valueDescription":"Progressive disease","ValueMeaning":{"publicId":"3260654","version":"1","preferredName":"Progressive disease","longName":"3260654","preferredDefinition":"New lesions that prove to be viable cancer and/or rise in the pretreatment tumor markers and/or greater than 25 percent increase in measurable lesions that are related to\r\nprogressive viable cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9C54027-EA99-5C4A-E040-BB89AD436EC6","latestVersionIndicator":"Yes","beginDate":"2011-08-05","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C54027-EAB1-5C4A-E040-BB89AD436EC6","beginDate":"2010-01-12","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"ONEDATA","dateModified":"2011-08-05","deletedIndicator":"No"},{"value":"Stable disease","valueDescription":"Stable disease","ValueMeaning":{"publicId":"3260655","version":"1","preferredName":"Stable disease","longName":"3260655","preferredDefinition":"Tumor regression not fulfilling the requirement for partial response or tumor progression less than 25 percent increase in the bidimensionally measurable tumor parameters","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9C54027-EABB-5C4A-E040-BB89AD436EC6","latestVersionIndicator":"Yes","beginDate":"2011-08-05","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A9C54027-EAD3-5C4A-E040-BB89AD436EC6","beginDate":"2010-01-12","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-05","modifiedBy":"ONEDATA","dateModified":"2011-08-05","deletedIndicator":"No"},{"value":"Not assessed","valueDescription":"Negation Assessment","ValueMeaning":{"publicId":"3049794","version":"1","preferredName":"Negation Assessment","longName":"3049794","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"836E0020-994D-2647-E040-BB89AD435E03","latestVersionIndicator":"Yes","beginDate":"2010-04-04","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2010-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B177CA04-200D-81A2-E040-BB89AD437C67","beginDate":"2011-09-01","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-11","modifiedBy":"ONEDATA","dateModified":"2011-11-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3420731","version":"1","preferredName":"Best Outcome of Therapy Malignant Testicular Germ Cell Tumor Status Type","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.:A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor. -- 2004:A condition or state at a particular time.:Something distinguishable as an identifiable class based on common qualities.","longName":"3420731v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Malignant Testicular Germ Cell Tumor","conceptCode":"C9063","definition":"A malignant germ cell tumor that arises from the testis. It predominantly affects young men. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBECA106-C0DF-4BDA-E040-BB89AD435E39","latestVersionIndicator":"Yes","beginDate":"2012-03-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-03-23","modifiedBy":"ONEDATA","dateModified":"2012-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CF9906D-DA5D-2D0C-E040-BB89AD43626A","latestVersionIndicator":"Yes","beginDate":"2010-01-12","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-12","modifiedBy":"KUMMEROA","dateModified":"2014-02-18","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964913","version":"1","longName":"2122r1: Testicular / Germ Cell Cancer Post-HSCT Data","context":"NHLBI"},{"publicId":"2964899","version":"1","longName":"2022r1: Testicular / Germ Cell Cancer Pre-HSCT Data","context":"NHLBI"},{"publicId":"3279271","version":"1","longName":"Disease Status","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"tc_base_tx_best_resp","type":"NMDP_FN","context":"NHLBI"},{"name":"tc_post_dx_best_rspns_kn","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:diseaseStatusCode ","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the testicular germ cell cancer best response to HSCT?","type":"Alternate Question Text","description":"What was the testicular germ cell cancer best response to HSCT?","url":null,"context":"NHLBI"},{"name":"What was the best outcome of","type":"Preferred Question Text","description":"What was the best outcome of therapy for the malignant testicular germ cell tumor?","url":null,"context":"NHLBI"},{"name":"What was the best response to HSCT?","type":"Alternate Question Text","description":"What was the best response to HSCT?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2984453","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis > AssessedResultRelationship > PerformedObservation > PerformedClinicalinterpretation.value = \"best result\" AND PerformedDiagnosis.value = \"testicular germ cell cancer\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CF9C71E-CE54-0C31-E040-BB89AD432178","latestVersionIndicator":"Yes","beginDate":"2010-01-12","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-12","modifiedBy":"KUMMEROA","dateModified":"2021-06-17","changeDescription":". Added alt name for 2022. AK 6/30/16 System generated def displayed as alt def. 2021-6-17 ak","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}